The Impact of Emerging Bioassay Technologies Presented by Catalent Expert at WCBP Conference
Somerset, NJ, January 29, 2013
– Michael Sadick, PhD, Senior Manager, Biopharmaceutical Characterization, Catalent Pharma Solutions, is to present at the WCBP conference in Washington, DC, on Wednesday, January 29, 2013.
Dr. Sadick’s presentation, entitled “Establishment and Optimization of a Potency Assay for an Effector mAb Using "ADCC Reporter Bioassay,” will detail the adaptation of the Promega ADCC NFAT-Luciferase system to the real world case of a client effector mAb therapeutic that required a more quantitative, robust accurate and rapid potency assay than could be provided using a classical lytic ADCC assay. The strategies utilized to optimize the method will be explained, as will be the potential advantages of using this assay system.
The WCBP conference is the pre-eminent conference addressing the analytical development/regulatory control interface for biotechnology derived health intervention products. The goal of this Symposium series is to provide a forum for discussing the latest analytical methods and their practical application to biotechnology pharmaceuticals and other health related products. Both state-of-the-art innovations as well as conventional technologies addressing research and routine testing applications will be covered.
Catalent has more than 75 years’ experience and a wide range of innovative drug delivery solutions to improve product performance. The talent and expertise of more than 1,000 development and formulation scientists has helped solve some of the most complex bioavailability challenges and deliver effective treatments.
The WCBP Conference takes place from January, 28 – 30, 2013 at the Mayflower Hotel in Washington, DC. For more information on the workshop or conference see http://bit.ly/UxbyJg .
To schedule an interview with the above mentioned presenter, or obtain a copy of the presentation after the event please contact Chris Halling at email@example.com
Click here for more information on Catalent’s biopharmaceutical laboratory services.
Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products. With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 9,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com .